Abstract68Ga-labeled DOTA-ibandronic acid (68Ga-DOTA-IBA) is a novel PET agent developed for bone tumors. In addition, 68Ga-DOTA-IBA uptake in nonosseous findings has also been reported. Herein, we present a case of 68Ga-DOTA-IBA uptake in primary prostate adenocarcinoma.

01 Nov 2024·European Journal of Nuclear Medicine and Molecular Imaging

Multi-modality deep learning-based [68Ga]Ga-DOTA-FAPI-04 PET polar map generation: potential value in detecting reactive fibrosis after myocardial infarction

Article

Author: Wang, Hanzhong ; Meng, Hongping ; Li, Biao ; Zhang, Min ; Yan, Xiaoxiang ; Xi, Yun ; Qiao, Xiaoya ; Huang, Qiu ; Feng, David Dagan

PURPOSEGenerating polar map (PM) from [⁶⁸Ga]Ga-DOTA-FAPI-04 PET images is challenging and inaccurate using existing automatic methods that rely on the myocardial anatomical integrity in PET images. This study aims to enhance the accuracy of PM generated from [⁶⁸Ga]Ga-DOTA-FAPI-04 PET images and explore the potential value of PM in detecting reactive fibrosis after myocardial infarction and assessing its relationship with cardiac function.METHODSWe proposed a deep-learning-based method that fuses multi-modality images to compensate for the cardiac structural information lost in [⁶⁸Ga]Ga-DOTA-FAPI-04 PET images and accurately generated PMs. We collected 133 pairs of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/MR images from 87 ST-segment elevated myocardial infarction patients for training and evaluation purposes. Twenty-six patients were selected for longitudinal analysis, further examining the clinical value of PM-related imaging parameters.RESULTSThe quantitative comparison demonstrated that our method was comparable with the manual method and surpassed the commercially available software-PMOD in terms of accuracy in generating PMs for [⁶⁸Ga]Ga-DOTA-FAPI-04 PET images. Clinical analysis revealed the effectiveness of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET PM in detecting reactive myocardial fibrosis. Significant correlations were demonstrated between the difference of baseline PM FAPI% and PM LGE%, and the change in cardiac function parameters (all p < 0.001), including LVESV% (r = 0.697), LVEDV% (r = 0.621) and LVEF% (r = -0.607).CONCLUSIONThe [⁶⁸Ga]Ga-DOTA-FAPI-04 PET PMs generated by our method are comparable to manually generated and sufficient for clinical use. The PMs generated by our method have potential value in detecting reactive fibrosis after myocardial infarction and were associated with cardiac function, suggesting the possibility of enhancing clinical diagnostic practices.TRIAL REGISTRATIONClinicalTrials.gov (NCT04723953). Registered 26 January 2021.

01 Nov 2024·Clinical Nuclear Medicine

Increased Uptake of 68Ga-DOTA-IBA in Multiple Subcutaneous Metastases of Prostate Cancer

Article

Author: Shang, Xiaoyan ; Chen, Yue ; Wang, Wei ; Liu, Huipan ; Liu, Yuhong

AbstractSubcutaneous metastases are rare in prostate cancer. Herein, we present a case of a 66-year-old man with prostate cancer, who underwent 68Ga-labeled DOTA-ibandronic acid (68Ga-DOTA-IBA) PET/CT to explore the possibility of 177Lu-DOTA-IBA treatment. 68Ga-DOTA-IBA PET/CT demonstrated intensely increased uptake in the multiple osteoblastic bone metastases. Unexpectedly, 68Ga-DOTA-IBA uptake in multiple subcutaneous metastases was also noted.

100 Deals associated with [68Ga]-DOTA-IBA

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bone metastases	Preclinical	US	Southwest Medical University	24 May 2023
Bone metastases	Preclinical	CN	Southwest Medical University	24 May 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

[68Ga]-DOTA-IBA

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation